Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8604772 | Cor et Vasa | 2018 | 6 Pages |
Abstract
In the ACS patients studied, we found a mortality benefit with the two newer oral P2Y12 inhibitors prasugrel and ticagrelor when compared with clopidogrel, which increases progressively as the underlying risk of death increases. This appears to be a class effect for these two newer agents.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
J. Wouter Jukema, Hannes Alber, Petr Widimský,